ScPharmaceuticals

ScPharmaceuticals

Infused therapies —bringing them to a better place, a new *sight* of care. Learn more

Launch date
Employees
Market cap
$275m
Enterprise valuation
$278m (Public information from Sep 2024)
Burlington Massachusetts (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues---13.6m39.4m96.6m186m
% growth----190 %145 %93 %
EBITDA(29.6m)(25.5m)(33.5m)(46.1m)(54.0m)(33.4m)10.7m
% EBITDA margin---(339 %)(137 %)(35 %)6 %
Profit(32.2m)(28.0m)(36.8m)(54.8m)(61.0m)(36.8m)28.2m
% profit margin---(403 %)(155 %)(38 %)15 %
EV / revenue---16.5x6.5x2.6x1.4x
EV / EBITDA-4.9x-5.4x-7.3x-4.9x-4.7x-7.6x23.8x
R&D budget18.1m16.0m15.5m11.8m---
R&D % of revenue---87 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-

$16.0m

Series A

$45.6m

Series B
N/A

$90.0m

IPO
*

$20.0m

Post IPO Debt
*
N/A

$50.0m

Post IPO Equity
*

$100m

Post IPO Debt
*
N/A

$50.0m

Post IPO Equity
*
N/A

$50.0m

-
Total Funding$112m

Recent News about ScPharmaceuticals

Edit
More about ScPharmaceuticalsinfo icon
Edit

scPharmaceuticals is a pharmaceutical company dedicated to developing and commercializing innovative solutions aimed at enhancing outpatient care. The company focuses on creating proprietary subcutaneous furosemide treatments for heart failure (HF) diuresis, delivered via an on-body infusor. This technology allows patients to receive necessary treatments outside of a hospital setting, improving comfort and maintaining dignity during recuperation. scPharmaceuticals primarily serves patients with heart failure, targeting the outpatient care market. The business model revolves around the development and sale of its proprietary drug delivery systems, generating revenue through product sales and potentially through partnerships or licensing agreements. By shifting care from inpatient to outpatient settings, scPharmaceuticals aims to transform disease management and reduce healthcare costs.

Keywords: subcutaneous furosemide, heart failure, outpatient care, on-body infusor, pharmaceutical innovation, HF diuresis, patient comfort, healthcare cost reduction, proprietary treatments, disease management.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.